Military hospitals known as the Combined Military Hospital are Pakistan Armed Forces hospitals situated in various cantonments of Pakistan. A legacy of the British Empire, these hospitals were originally established for British troops. After becoming the Indian Army Medical Corps (IAMC), they were situated in areas that became part of Pakistan and now are known as the Combined Military Hospitals, Pakistan. Today, they offer vital medical treatment, such as in-patient and out-patient medical and surgical treatment to the military and the civilian population of Pakistan: representing millions of people. Just last month, the government provider launched a clinical trial to investigate the efficacy of ivermectin in COVID-19 patients.
COVID-19 in Pakistan
With reported cases just under 65,000, Pakistan has experienced 1,317 deaths as of this writing. For more information on the ongoing pandemic there, see Wikipedia with a decent overview. One of the world’s most populous countries with about 212 million, the nation’s economy as measured by GDP, struggles and must be proactive in overcoming SARS-CoV-2 to normalize its economy. There are conflicting signals from the country, much like in other countries, where some groups downplay the invisible pathogen’s menace, while others do not. While malls open on the one hand, on the other concerns of social and economic displacement as well as health risks are significant.
This randomized, controlled trial has been designed to investigate the efficacy of ivermectin in COVID-19 patients. Patients will be assigned to two groups, including 1) that will be given ivermectin with standard chloroquine regimen, and 2) the other group will be given chloroquine only. The outcomes will be recorded by documenting PCR reports at 48, 96 and 144 hours.
The study was launched April 15, 2020 and runs till July 2020. Recruiting 100 patients, the study precludes those with severe conditions or comorbidities such as malignant disease, diabetes, etc.
Najma Parveen, FCPS, MED, Principal Investigator
Karamat Hu Bukhari, FCPS, MED, Study Director
Call to Action: TrialSite News is developing its own ivermectin registry strategy and monitors all of these ivermectin trials. As results are disclosed or available, we will report them. Sign up for the newsletter for daily updates.